At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 240 enrolled
Drug / intervention
MMH-407 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of MMH-407 in the Treatment of Acute Respiratory Viral Infection
In Brief
A Phase 3 clinical trial evaluating MMH-407 and Placebo for Viral Respiratory Infection. Completed, enrolled 240 participants across 26 sites.
Detailed Summary
To evaluate the efficacy and safety of ММН-407 in treatment of acute respiratory viral infection (ARVI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsViral Respiratory Infection
CountriesRussia
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartOct 2019
First PostedJan 2020
Primary CompletionApr 2020
TodayJul 2026
First PostedJan 28, 2020
Enrollment StartOct 8, 2019
Primary CompletionApr 9, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.4 years ago
Interventions
MMH-407drug
Oral use.
Placebodrug
Oral use.